Causes and triggers of secretion
The key trigger for the initiation of atrial natriuretic peptide secretion is physical stretch of the atrial walls. This condition naturally occurs in situations where there is a substantial increase in circulating blood volume (CBV) in the human body.
Specialized heart muscle cells—cardiomyocytes located in the atria—sensorily react to this mechanical stretch. In response to excess blood volume, they actively release atrial natriuretic peptide into the systemic circulation. Thus, the heart performs not only its basic pumping function but also acts as a vital endocrine organ capable of independently controlling excess fluid in the vascular bed.
Biochemical mechanism of action
The biochemical signaling mechanism of atrial natriuretic peptide differs from those of many other vasoactive molecules. Atrial natriuretic peptide does not penetrate inside the cell; instead, it interacts with specific membrane receptors located on the surface of target cells.
The binding of this hormone to the receptor leads to the direct activation of the enzyme guanylyl cyclase. As a result of this enzymatic reaction, a secondary messenger—cyclic guanosine monophosphate (cGMP)—begins to rapidly accumulate inside the cell. It is this accumulation of cGMP that drives all subsequent intracellular changes leading to physiological responses in target organs.
Important exam nuance: atrial natriuretic peptide does not activate the enzyme phospholipase C. This signaling pathway (via phospholipase C) is completely uncharacteristic of ANP, whereas it is actively utilized by other hormones, such as angiotensin II.
Systemic effects and target organs
Atrial natriuretic peptide works as a direct physiological antagonist of the renin-angiotensin-aldosterone system (RAAS). Its primary biological task is to counteract fluid retention and prevent the constriction of blood vessels. The biochemical action of atrial natriuretic peptide extends to several key organs and systems:
- Kidneys: at the level of renal tissue, there is potent inhibition of the release of the enzyme renin. Concurrently, atrial natriuretic peptide significantly enhances the excretion of sodium ions ($Na^+$) and water in the urine, which in medical terminology is called natriuresis and diuresis.
- Adrenal glands: at the level of the adrenal cortex, the hormone directly suppresses the secretion of aldosterone—the main hormone responsible for sodium retention in the body.
- Pituitary gland: atrial natriuretic peptide blocks the secretion of antidiuretic hormone (ADH), thereby preventing the reabsorption of water in the renal tubules.
- Blood vessels: the hormone causes relaxation of the smooth muscle of the vascular wall, leading to pronounced vasodilation (dilation) of peripheral arteries.
Mechanism of the hypotensive effect
The ultimate result of all the aforementioned biochemical and physiological processes is the development of a sustained hypotensive effect (reduction of elevated blood pressure). This effect is based on two fundamental mechanisms that operate synchronously.
Firstly, due to the active excretion of sodium ions and water (diuresis and natriuresis), the total blood volume naturally decreases. A smaller fluid volume exerts significantly less pressure on the walls of blood vessels. Secondly, vascular relaxation leads to peripheral arterial vasodilation, which increases the total capacity of the vascular bed. Combined, the reduced blood volume and arterial dilation effectively and quickly normalize blood pressure, relieving excessive strain on the heart muscle.
Briefly: answers to topical questions
What types of receptors does atrial natriuretic peptide bind to?
Atrial natriuretic peptide binds to specific membrane receptors of types A and B. These receptors are catalytic and possess intrinsic guanylyl cyclase activity.
- Type A and B receptors are localized on the plasma membrane of target cells, particularly in the endothelium and vascular smooth muscle cells (angiocytes).
The binding of the ligand to these transmembrane receptors stimulates the conversion of GTP into cyclic guanosine monophosphate, leading to a decrease in vascular tone.
Which enzyme is responsible for the degradation of atrial natriuretic peptide in the bloodstream?
The degradation of natriuretic peptides in the body is carried out by the enzyme neprilysin, also known as neutral endopeptidase. This enzyme cleaves endogenous vasodilating peptides. The blockade of neutral endopeptidase with specific drugs (e.g., sacubitril or omapatrilat) prevents the breakdown of natriuretic peptides, promoting enhanced vasodilation and an additional reduction in blood pressure.
What other types of natriuretic peptides exist in the body besides the atrial one?
In addition to atrial natriuretic peptide (type A), the following types are synthesized in the body:
- Brain natriuretic peptide (BNP, B-type peptide) is secreted by the ventricles of the heart in response to their overstretching.
- C-type peptide is synthesized by endotheliocytes.
Additionally, the N-terminal fragment of the brain natriuretic peptide prohormone (NT-proBNP) is determined as a marker in clinical practice.
To remember the effects of ANP, use the rule of three "H's" (in Russian starting with 'С': Heart (secretes the hormone upon stretch), Vessels (vasodilation occurs), Drainage (excretion of sodium and water by the kidneys). All these actions work strictly against the RAAS system.
Class and exam questions
What is the main trigger that induces the production of atrial natriuretic peptide?
The secretion of atrial natriuretic peptide is triggered by the mechanical stretch of atrial cardiomyocytes. This condition occurs when the circulating blood volume in the body increases.
Through which secondary messenger does this hormone act?
Atrial natriuretic peptide interacts with membrane receptors and activates the enzyme guanylyl cyclase. This leads to the intracellular accumulation of cGMP, which acts as the secondary messenger.
Why is atrial natriuretic peptide called an antagonist of the RAAS?
Because it produces effects completely opposite to the action of the renin-angiotensin-aldosterone system. It dilates blood vessels and also suppresses the production of renin, aldosterone, and ADH, stimulating the loss of sodium and water.
Does phospholipase C participate in the mechanism of action of atrial natriuretic peptide?
No, the activation of phospholipase C is completely uncharacteristic of atrial natriuretic peptide. This pathway is utilized by other hormones, notably angiotensin II.
What else to study on this topic
- Structure of guanylyl cyclase-linked membrane receptors.
- Mechanisms of suppressing renin secretion in the juxtaglomerular apparatus of the kidneys.
- Interaction of cGMP with protein kinases inside vascular smooth muscle cells.
- Differences in signaling pathways between ANP (cGMP) and Angiotensin II (phospholipase C).
Master the entire topic in the "Biochemistry" course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Atrial natriuretic peptide" and another 3,616 pages of the subject
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 115 video lessons on the subject
Other topics in the section "Hormonal Regulation of Metabolism and Body Functions"
Free video lessons: biochemistryShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.